ABLD.PA

AbL Diagnostics SA

ABLD.PA, France

ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA; ultragene assays for viral detection of SARS CoV-2, MonkeyPox, and Clostridium; microbiological specimen transport and collection kits, which include saliva preservation, wastewater collection, and surface collection kits, as well as inactivation and preservation solution; and instrument and consumables, such as DNA/RNA extraction system, real-time PCR system, liquid handling robot, NGS library preparation kit, and sanger sequencing reaction. It also provides digital solutions comprising analysis software, data hosting, lab automation, Nadis, and SeqHepB. The company sells its products directly, as well as through a network of distributors to academic clinical pathology labs, private reference labs, and researchers. The company was formerly known as Etablissements Fauvet Girel and changed its name to ABL Diagnostics Société anonyme in April 2022. The company is headquartered in Woippy, France. ABL Diagnostics Société anonyme is a subsidiary of Advanced Biological Laboratories (ABL) S.A.

https://www.abldiagnostics.com

Stock Price

€0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ABLD.PA
stock
ABLD.PA

Why ABLD stock appeals to dividend investors - 2025 Fundamental Recap & Low Risk Entry Point Guides bollywoodhelpline.com

Read more →
ABLD.PA
stock
ABLD.PA

Learn all about the PA ABLE Savings Program pahouse.com

Read more →

Finn Analysis

(Last Updated 2024-12-31)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

103.33

Low 50

High 10

Price to Book Ratio (P/B)

-

Very High

8.04

Low 1

High 3

Return on Equity (ROE)

-

Very Low

2.33 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

1.48 %

Low 2%

High 10%

Debt to Equity

-

High

0.58

Low 1

High 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of AbL Diagnostics SA

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2024-12-31)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Fair GARP(3.5)
Growth
Moderate Growth(3.5)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(3)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2024-12-31)

Revenue

€ 0

Cost Of Revenue

€ 0

Gross Profit

€ 0

Operating Expenses

€ 0

Operating Income

€ 0

Interest Expense

€ 0

Pretax Income

€ 0

Net Income

€ 0

Income Tax Expense

€ 0

EBITDA

€ 0

Total Other Income Expense Net

€ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-12-31)

Cash

0

Short Term Investments

0

Receivables

0

Inventories

0

Total Current Assets

0

Property Plant Equipment

0

Total Assets

0

Payables

0

Short Term Debt

0

Long Term Debt

0

Total Liabilities

0

Equity

0

Trend

Cash Flow

(Last Updated 2024-12-31)

Net Income

0

Depreciation

0

Change In Working Capital

0

Cash From Operations

0

Capital Expenditures

0

Cash From Investing

0

Cash From Financing

0

Net Change In Cash

0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.